首頁 > 市場調查報告書 > 製藥

孤兒藥

市場調查報告書

商品編碼

1746589

日本孤兒藥市場報告（按藥物類型、疾病類型、階段、暢銷藥物、配銷通路和地區分類）2025-2033

Japan Orphan Drugs Market Report by Drug Type, Disease Type, Phase, Top Selling Drug, Distribution Channel, and Region 2025-2033

出版日期: 2025年06月02日 | 出版商:

IMARC | 英文 117 Pages | 商品交期: 5-7個工作天內

價格

簡介目錄

2024年，日本孤兒藥市場規模達140.34億美元。展望未來， IMARC Group預計到2033年，該市場規模將達到326.87億美元，2025-2033年期間的複合年成長率（CAGR）為9.8%。缺乏治療的罕見疾病數量不斷增加，以及醫療保健可近性的改善，是推動市場發展的關鍵因素。

孤兒藥是用於診斷、預防和治療罕見疾病的藥物。這些藥物旨在滿足特定的醫療保健需求，由於僅供少數患者使用，市場通常有限。它們已被證明可有效治療多種疾病，包括但不限於腫瘤、代謝、血液、免疫、感染和神經系統疾病。此外，許多罕見疾病，如淋巴瘤、白血病、囊性纖維化、神經膠質瘤、胰臟癌、卵巢癌、多發性骨髓瘤和腎細胞癌，通常具有危及生命、慢性、進行性、退化性及致殘性。這些疾病需要針對其獨特症狀的專門治療方案。因此，孤兒藥在日本各地的醫院中被廣泛使用。

日本孤兒藥市場趨勢：

在日本市場，多種因素正在推動市場成長。其中一個重要促進因素是癌症和罕見遺傳疾病的發生率不斷上升。製藥商正在積極開發創新孤兒藥，為患者提供個人化治療方案，以滿足日益成長的需求，從而對區域市場產生了積極影響。此外，大眾對孤兒藥優勢的認知不斷提高，也促進了市場的成長。此外，新製藥公司的湧現以及政府為遏制傳染病傳播而推出的優惠政策，也促進了這一積極的成長軌跡。除了這些因素之外，各種產品創新，例如生物孤兒藥的研發，也成為額外的成長催化劑。這些藥物能夠治療癌症等疾病，並逆轉幹細胞的損傷，從而顯著提升了對此類藥物的需求，這也是另一個重要的成長誘因。此外，醫療基礎設施的改善以及對研發活動的大力投入預計將進一步推動市場擴張。

日本孤兒藥市場細分：

藥物類型洞察：

生物
非生物

疾病類型洞察：

腫瘤學
血液學
神經病學
心血管
其他

階段洞察：

第一階段
第二階段
第三階段
第四階段

暢銷藥品洞察：

來那度胺
利妥昔單抗
克帕松
奧狄沃
可瑞達
依魯替尼
艾沃尼克斯
森西帕爾
索立利
其他

配銷通路洞察：

醫院藥房
零售藥局
網路商店
其他

競爭格局：

市場研究報告也對市場競爭格局進行了全面分析。報告涵蓋了市場結構、關鍵參與者定位、最佳制勝策略、競爭指標和公司評估象限等競爭分析。此外，報告還提供了所有主要公司的詳細資料。

本報告回答的關鍵問題：

日本孤兒藥市場目前表現如何？未來幾年將如何表現？
COVID-19 對日本孤兒藥市場有何影響？
日本孤兒藥市場如何依藥品類型分類？
日本孤兒藥市場如何依疾病類型分類？
日本孤兒藥市場以階段分類是怎樣的？
根據最暢銷的藥物，日本孤兒藥市場是如何分類的？
日本孤兒藥市場依照配銷通路的分佈是怎樣的？
日本孤兒藥市場的價值鏈分為哪些階段？
日本孤兒藥的關鍵促進因素和挑戰是什麼？
日本孤兒藥市場的結構是怎麼樣的？主要參與者是誰？
日本孤兒藥市場的競爭程度如何？

本報告回答的關鍵問題：

日本孤兒藥市場目前表現如何？未來幾年將如何表現？
COVID-19 對日本孤兒藥市場有何影響？
日本孤兒藥市場如何依藥品類型分類？
日本孤兒藥市場如何依疾病類型分類？
日本孤兒藥市場以階段分類是怎樣的？
根據最暢銷的藥物，日本孤兒藥市場是如何分類的？
日本孤兒藥市場依照配銷通路的分佈是怎樣的？
日本孤兒藥市場的價值鏈分為哪些階段？
日本孤兒藥的關鍵促進因素和挑戰是什麼？
日本孤兒藥市場的結構是怎麼樣的？主要參與者是誰？
日本孤兒藥市場的競爭程度如何？

Japan orphan drugs market size reached USD 14,034 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 32,687 Million by 2033, exhibiting a growth rate (CAGR) of 9.8% during 2025-2033. The rising number of rare diseases lacking treatment, along with improving access to healthcare, represent some of the key factors driving the market.

Orphan drugs are pharmaceutical products designed for the diagnosis, prevention, and treatment of rare medical conditions. These medications are developed to address specific healthcare needs and typically have a limited market because they are intended for a small number of patients. They prove effective against a wide range of medical conditions, including but not limited to oncological, metabolic, hematologic, immunologic, infectious, and neurological diseases. In addition to this, many of these conditions, such as lymphoma, leukemia, cystic fibrosis, glioma, pancreatic cancer, ovarian cancer, multiple myeloma, and renal cell carcinoma, are often life-threatening, chronic, progressive, degenerative, and disabling. They necessitate specialized treatment options that are tailored to address their unique symptoms. Consequently, orphan drugs are widely utilized in hospitals across Japan.

Japan Orphan Drugs Market Trends:

In the context of the Japan market, several factors are fueling market growth. One significant driver is the increasing prevalence of cancer and rare genetic disorders. Pharmaceutical manufacturers are actively developing innovative orphan drugs to offer personalized therapy options to patients in response to this growing demand, thereby positively influencing the regional market. Furthermore, the market is benefiting from heightened public awareness of the advantages of orphan drugs. Besides this, the emergence of new pharmaceutical companies in the market and the implementation of favorable government policies aimed at curbing the spread of contagious diseases are also contributing to this positive growth trajectory. In addition to these factors, various product innovations, such as the creation of biological orphan drugs, are serving as additional growth catalysts. These drugs have the capacity to treat diseases like cancer and reverse the damage inflicted on stem cells, significantly boosting their demand, which is acting as another significant growth-inducing factor. Moreover, improvements in healthcare infrastructure and a substantial focus on research and development (R&D) activities are expected to further propel the market's expansion.

Japan Orphan Drugs Market Segmentation:

Drug Type Insights:

Biological
Non-Biological

Disease Type Insights:

Oncology
Hematology
Neurology
Cardiovascular
Others

Phase Insights:

Phase I
Phase II
Phase III
Phase IV

Top Selling Drugs Insights:

Revlimid
Rituxan
Copaxone
Opdivo
Keytruda
Imbruvica
Avonex
Sensipar
Soliris
Others

Distribution Channel Insights:

Hospital Pharmacies
Retail Pharmacies
Online Stores
Others

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

How has the Japan orphan drugs market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Japan orphan drugs market?
What is the breakup of the Japan orphan drugs market on the basis of drug type?
What is the breakup of the Japan orphan drugs market on the basis of disease type?
What is the breakup of the Japan orphan drugs market on the basis of phase?
What is the breakup of the Japan orphan drugs market on the basis of top selling drugs?
What is the breakup of the Japan orphan drugs market on the basis of distribution channel?
What are the various stages in the value chain of the Japan orphan drugs market?
What are the key driving factors and challenges in the Japan orphan drugs?
What is the structure of the Japan orphan drugs market and who are the key players?
What is the degree of competition in the Japan orphan drugs market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Orphan Drugs Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Orphan Drugs Market Landscape

5.1 Historical and Current Market Trends (2019-2024)
5.2 Market Forecast (2025-2033)

6 Japan Orphan Drugs Market - Breakup by Drug Type

6.1 Biological
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2019-2024)
- 6.1.3 Market Forecast (2025-2033)
6.2 Non-Biological
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2019-2024)
- 6.2.3 Market Forecast (2025-2033)

7 Japan Orphan Drugs Market - Breakup by Disease Type

7.1 Oncology
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2019-2024)
- 7.1.3 Market Forecast (2025-2033)
7.2 Hematology
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2019-2024)
- 7.2.3 Market Forecast (2025-2033)
7.3 Neurology
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2019-2024)
- 7.3.3 Market Forecast (2025-2033)
7.4 Cardiovascular
- 7.4.1 Overview
- 7.4.2 Historical and Current Market Trends (2019-2024)
- 7.4.3 Market Forecast (2025-2033)
7.5 Others
- 7.5.1 Historical and Current Market Trends (2019-2024)
- 7.5.2 Market Forecast (2025-2033)

8 Japan Orphan Drugs Market - Breakup by Phase

8.1 Phase I
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2019-2024)
- 8.1.3 Market Forecast (2025-2033)
8.2 Phase II
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2019-2024)
- 8.2.3 Market Forecast (2025-2033)
8.3 Phase III
- 8.3.1 Overview
- 8.3.2 Historical and Current Market Trends (2019-2024)
- 8.3.3 Market Forecast (2025-2033)
8.4 Phase IV
- 8.4.1 Overview
- 8.4.2 Historical and Current Market Trends (2019-2024)
- 8.4.3 Market Forecast (2025-2033)

9 Japan Orphan Drugs Market - Breakup by Top Selling Drugs

9.1 Revlimid
- 9.1.1 Overview
- 9.1.2 Historical and Current Market Trends (2019-2024)
- 9.1.3 Market Forecast (2025-2033)
9.2 Rituxan
- 9.2.1 Overview
- 9.2.2 Historical and Current Market Trends (2019-2024)
- 9.2.3 Market Forecast (2025-2033)
9.3 Copaxone
- 9.3.1 Overview
- 9.3.2 Historical and Current Market Trends (2019-2024)
- 9.3.3 Market Forecast (2025-2033)
9.4 Opdivo
- 9.4.1 Overview
- 9.4.2 Historical and Current Market Trends (2019-2024)
- 9.4.3 Market Forecast (2025-2033)
9.5 Keytruda
- 9.5.1 Overview
- 9.5.2 Historical and Current Market Trends (2019-2024)
- 9.5.3 Market Forecast (2025-2033)
9.6 Imbruvica
- 9.6.1 Overview
- 9.6.2 Historical and Current Market Trends (2019-2024)
- 9.6.3 Market Forecast (2025-2033)
9.7 Avonex
- 9.7.1 Overview
- 9.7.2 Historical and Current Market Trends (2019-2024)
- 9.7.3 Market Forecast (2025-2033)
9.8 Sensipar
- 9.8.1 Overview
- 9.8.2 Historical and Current Market Trends (2019-2024)
- 9.8.3 Market Forecast (2025-2033)
9.9 Soliris
- 9.9.1 Overview
- 9.9.2 Historical and Current Market Trends (2019-2024)
- 9.9.3 Market Forecast (2025-2033)
9.10 Others
- 9.10.1 Historical and Current Market Trends (2019-2024)
- 9.10.2 Market Forecast (2025-2033)

10 Japan Orphan Drugs Market - Breakup by Distribution Channel

10.1 Hospital Pharmacies
- 10.1.1 Overview
- 10.1.2 Historical and Current Market Trends (2019-2024)
- 10.1.3 Market Forecast (2025-2033)
10.2 Retail Pharmacies
- 10.2.1 Overview
- 10.2.2 Historical and Current Market Trends (2019-2024)
- 10.2.3 Market Forecast (2025-2033)
10.3 Online Stores
- 10.3.1 Overview
- 10.3.2 Historical and Current Market Trends (2019-2024)
- 10.3.3 Market Forecast (2025-2033)
10.4 Others
- 10.4.1 Historical and Current Market Trends (2019-2024)
- 10.4.2 Market Forecast (2025-2033)

11 Japan Orphan Drugs Market - Competitive Landscape

11.1 Overview
11.2 Market Structure
11.3 Market Player Positioning
11.4 Top Winning Strategies
11.5 Competitive Dashboard
11.6 Company Evaluation Quadrant

12 Profiles of Key Players

12.1 Company A
- 12.1.1 Business Overview
- 12.1.2 Product Portfolio
- 12.1.3 Business Strategies
- 12.1.4 SWOT Analysis
- 12.1.5 Major News and Events
12.2 Company B
- 12.2.1 Business Overview
- 12.2.2 Product Portfolio
- 12.2.3 Business Strategies
- 12.2.4 SWOT Analysis
- 12.2.5 Major News and Events
12.3 Company C
- 12.3.1 Business Overview
- 12.3.2 Product Portfolio
- 12.3.3 Business Strategies
- 12.3.4 SWOT Analysis
- 12.3.5 Major News and Events
12.4 Company D
- 12.4.1 Business Overview
- 12.4.2 Product Portfolio
- 12.4.3 Business Strategies
- 12.4.4 SWOT Analysis
- 12.4.5 Major News and Events
12.5 Company E
- 12.5.1 Business Overview
- 12.5.2 Product Portfolio
- 12.5.3 Business Strategies
- 12.5.4 SWOT Analysis
- 12.5.5 Major News and Events

13 Japan Orphan Drugs Market - Industry Analysis

13.1 Drivers, Restraints, and Opportunities
- 13.1.1 Overview
- 13.1.2 Drivers
- 13.1.3 Restraints
- 13.1.4 Opportunities
13.2 Porters Five Forces Analysis
- 13.2.1 Overview
- 13.2.2 Bargaining Power of Buyers
- 13.2.3 Bargaining Power of Suppliers
- 13.2.4 Degree of Competition
- 13.2.5 Threat of New Entrants
- 13.2.6 Threat of Substitutes
13.3 Value Chain Analysis